Spyre Therapeutics, Inc. SYRE
103.86 USD +7.27 (+7.53%)
At closeNov 6, 2026, 5:48 PM EST
103.00 -0.86 -0.83%
After hours · Nov 6, 5:48 PM ET
97.29 Day range 104.25
22.18 52-week range 108.92
- YTD
- +217.03%
- 1 year
- +363.87%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 123.20 +18.6% upside
Now 103.86
- Target (low)
- 110.00
- Target (mean)
- 123.20
- Target (high)
- 135.00
Ratings (0m) 18 17 buy · 1 hold · 0 sell
- Strong buy1
- Buy16
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 18
- 2 months ago 16
- 3 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.96321 | -1.91 – -0.50 | -0.74 | -30.2% | 0 | 0.0% | 13 |
| Next quarter | -0.86827 | -1.10 – -0.67309 | -0.74 | -17.3% | 0 | 0.0% | 4 |
| Current year | -2.95 | -3.95 – -2.52 | -1.98 | -48.9% | 0 | 0.0% | 13 |
| Next year | -3.64 | -4.55 – -2.36 | -2.95 | -23.3% | 0 | 0.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Guggenheim | Maintained | Buy | Buy |
| Nov 4, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Oct 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Oct 12, 2026 | UBS | Initiated | — | Buy |
| Oct 1, 2026 | JP Morgan | Initiated | — | Overweight |
| Oct 1, 2026 | BTIG | Reiterated | Buy | Buy |
| Sep 9, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 8, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 26, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Aug 26, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 26, 2026 | BTIG | Maintained | Buy | Buy |
| Aug 11, 2026 | BTIG | Maintained | Buy | Buy |
| Aug 5, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 5, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 28, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Jul 13, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jun 23, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Jun 15, 2026 | BTIG | Maintained | Buy | Buy |
| Jun 4, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| May 6, 2026 | Citigroup | Maintained | Buy | Buy |
| May 6, 2026 | Stifel | Maintained | Buy | Buy |
| Apr 17, 2026 | Jones Trading | Maintained | Buy | Buy |
| Apr 14, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Baird | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Raymond James | Initiated | — | Strong Buy |
| Apr 14, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Apr 13, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Apr 13, 2026 | Jefferies | Maintained | Buy | Buy |